CEL-SCI Corporation today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments.
Clinical and Corporate Developments this quarter.
StockNews.com upgraded shares of CEL-SCI (NYSE:CVM – Free Report) from a sell rating to a hold rating in a report published on Tuesday. CEL-SCI Stock Down 5.1 % CVM stock opened at $1.49 on Tuesday. CEL-SCI has a 52-week low of $1.45 and a 52-week high of $5.42. The company’s 50 day simple moving average […]
StockNews.com downgraded shares of CEL-SCI (NYSE:CVM – Free Report) from a hold rating to a sell rating in a research note published on Monday morning. CEL-SCI Price Performance Shares of CVM stock opened at $1.71 on Monday. CEL-SCI has a 1-year low of $1.68 and a 1-year high of $5.42. The company has a current […]
CEL-SCI Announces Closing of Public Offering pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
VIENNA, Va. (BUSINESS WIRE) $CVM CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriter a 45-day opti.